High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis

Medizinische Klinik und Poliklinik I der Rheinischen Friedrich-Wilhelms-Universitat Bonn, Germany.

BACKGROUND AND OBJECTIVES: High-dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) has proven to be superior to conventional chemotherapy in patients with chemosensitive relapse of aggressive non-Hodgkin's lymphoma (NHL). Therefore, HDT/ASCT was evaluated as part of first-line therapy. Several trials generated conflicting results. This meta-analysis summarizes the available evidence from all suitable studies. DESIGN AND METHODS: Prospective, randomized trials with HDT/ASCT as first-line therapy of aggressive lymphoma were included in this meta-analysis. The primary outcome was overall mortality. Statistical analysis applied the odds ratio (OR) and a fixed effects model. RESULTS: Eleven trials with 2228 patients were eligible for meta-analysis. Overall mortality was comparable in the HDT/ASCT and in control arms (OR=0.97, 95% CI: 0.69;1.36, p=0.9), with statistically significant heterogeneity between the trials. To resolve this, we tried to identify variables that could explain this heterogeneity. Among a range of methodological, patient- or treatment-related factors, subgroups formed by the proportion of bulky disease in treated patients, the type of therapy prior to HDT/ASCT, the drop-out rate from the HDT/ASCT arm, and the presence of high or high-intermediate risk IPI showed significant benefit for any of the treatment modalities. However, such post-hoc subgroup analysis may be considerably influenced by random or systemic biases. INTERPRETATION AND CONCLUSIONS: Overall, the analysis of published evidence reveals very heterogeneous results and no overall survival benefit. Therefore, HDT/ASCT cannot be recommended as standard first line treatment for patients with aggressive NHL. However, the exploratory analyses presented here may help to design new trials for this treatment modality.

This article has been cited by other articles:

				C. Tarella, M. Zanni, M. Magni, F. Benedetti, C. Patti, T. Barbui, A. Pileri, M. Boccadoro, F. Ciceri, A. Gallamini, et al. Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innnovative nei Linfomi Survey J. Clin. Oncol., July 1, 2008; 26(19): 3166 - 3175. [Abstract] [Full Text] [PDF]

				B. Sirohi, D. Cunningham, R. Powles, F. Murphy, T. Arkenau, A. Norman, J. Oates, A. Wotherspoon, and A. Horwich Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma Ann. Onc., July 1, 2008; 19(7): 1312 - 1319. [Abstract] [Full Text] [PDF]

				D. Aguiar Bujanda, U. Bohn Sarmiento, J. Aguiar Morales, J. Bolanos-Meade, Y. Herishanu, A. Zomas, A. Skandalis, and N. Milpied Intensive Therapy for Aggressive Lymphoma N. Engl. J. Med., July 1, 2004; 351(1): 98 - 100. [Full Text] [PDF]